Developing novel therapeutics from the human microbiome
The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity.
Microba has established a platform for drug discovery and development that leverages a growing, proprietary Databank of human microbiome samples and associated metadata.
Precision techniques enable access to novel microbial therapeutic leads and rapid progression from identified lead to isolated monoclonal bacterial strain.
- Cross-validation and confidence in clinical progression
- State-of-the-art facilities for anaerobic microbiology
- Proprietary genome-directed isolation (GDI) approach
- Team expertise in culturing fastidious gut microbes
Human first, data-driven approach
Global databank of microbiome samplesOver 15,000 consistently collected human metagenomes analysed with our world-leading microbiome profiling technology.
Data-driven lead identificationAdvanced bioinformatics, AI and biostatistics identify the key species and sub species which differentiate healthy and diseased individuals.
Genome-directed isolation techniqueState-of-the-art facilities and proprietary genome-directed isolation approach to expedite the isolation of novel gut bacteria.
Biobank of isolatesBiobank from healthy donor stool material containing novel microbial isolate cultures which represent potential therapeutic candidates.
Lead characterisationRange of experimental models (in vitro, ex vivo and in vivo) to characterise potential therapeutic activities.
ManufacturabilityDetailed assessment to identify the most efficacious leads with strong manufacturing characteristics.